Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00794495
First received: November 19, 2008
Last updated: April 25, 2014
Last verified: April 2014

November 19, 2008
April 25, 2014
December 2002
July 2003   (final data collection date for primary outcome measure)
The primary efficacy measure was the preference rates calculated from subject comparative evaluation. [ Time Frame: 1 day after the last treatment period (Visit 5) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00794495 on ClinicalTrials.gov Archive Site
Subject Non-Comparative Evaluation and subject Response to Therapy [ Time Frame: 1 day after the end of each 7-day treatment period (Visit 3 and Visit 5) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)
Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis

This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis
  • Drug: Desloratadine 5 mg (Clarinex)
    Clarinex 5 mg daily x 7 days
    Other Name: Clarinex, SCH 34117
  • Drug: Cetirizine (Zyrtec)
    Zyrtec 10 mg daily x 7 days
    Other Name: Zyrtec®
  • Experimental: Clarinex followed by Zyrtec
    Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
    Interventions:
    • Drug: Desloratadine 5 mg (Clarinex)
    • Drug: Cetirizine (Zyrtec)
  • Experimental: Zyrtec followed by Clarinex
    Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
    Interventions:
    • Drug: Desloratadine 5 mg (Clarinex)
    • Drug: Cetirizine (Zyrtec)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
122
July 2003
July 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • had at least a two-year history of seasonal allergic rhinitis and/or perennial allergic rhinitis;
  • currently experiencing symptoms of AR, including nasal symptoms at Visits 2 and 4, prior to entering each treatment phase;
  • had not taken Zyrtec® or Clarinex® within the previous year;
  • were 18 years of age or older;
  • had negative urine test (hCG) for females of childbearing potential;
  • for women of childbearing potential, agreed to use a medically accepted method of birth control;
  • were free of any clinically significant disease (other than AR) that would interfere with study evaluations.

Exclusion Criteria:

  • were pregnant or nursing;
  • had allergic or idiosyncratic reaction to antihistamines;
  • had current or history of frequent, clinically significant sinusitis or chronic purulent nasal discharge;
  • had rhinitis medicamentosa or nasal structural abnormalities (including large nasal polyps and marked septal deviation) that significantly interfered with nasal airflow;
  • in the opinion of the Investigator, were dependent upon nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids (ie, subjects who could or would not observe the washout period for these prohibited medications);
  • had an upper respiratory tract or sinus infection that required antibiotic therapy with the last dose within 14 days prior to Screening, or had a viral upper respiratory infection within 7 days prior to Screening;
  • had asthma, unless their symptoms could be controlled by a short-acting inhaled Beta2-agonist used on an "as needed" basis;
  • were on immunotherapy, unless they were on a stable maintenance schedule prior to screening. The dose of immunotherapy should remain constant and subjects could not receive immunotherapy within 24 hours prior to any visit;
  • had a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that were likely to limit the validity of consent to participate in the study;
  • had a history of non-compliance with medications or treatment protocols;
  • had any clinically significant deviation from normal in the physical examination that, in the Investigator's judgment, may have interfered with the study evaluations or affect subject safety;
  • had any clinically significant metabolic, cardiovascular, immunologic, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the Investigator, might interfere with the study evaluations or affect subject safety;
  • had liver or renal impairment.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00794495
P03181
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP